IV 
116TH CONGRESS 
1ST SESSION 
H. RES. 214 
Supporting the goals to protect United States military personnel from malaria. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 11, 2019 
Mr. PANETTA (for himself and Mr. MAST) submitted the following resolution; 
which was referred to the Committee on Foreign Affairs, and in addition 
to the Committees on Armed Services, and Energy and Commerce, for 
a period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
RESOLUTION 
Supporting the goals to protect United States military 
personnel from malaria. 
Whereas fighting malaria is in the national interest of the 
United States; 
Whereas reducing the incidence of malaria protects United 
States servicemembers deployed to malaria-endemic re-
gions; 
Whereas the ‘‘World malaria report 2018’’ by the World 
Health Organization states that, in 2017, approximately 
435,000 people died of malaria; 
VerDate Sep 11 2014 
01:43 Mar 12, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR214.IH
HR214
pamtmann on DSKBFK8HB2PROD with BILLS
•HRES 214 IH 
Whereas, since 1893, the Walter Reed Army Institute of Re-
search (WRAIR) has played a leadership role protecting 
United States servicemembers from the world’s most per-
vasive infectious diseases, including malaria, HIV/AIDS, 
Ebola, and dengue; 
Whereas WRAIR Center for Infectious Disease Research has 
been responsible for developing critical Food and Drug 
Administration-approved medicines, vaccines, drugs, and 
other interventions used to prevent malaria, Japanese en-
cephalitis, hepatitis A, adenovirus, and other infectious 
diseases in deployed servicemembers; 
Whereas the WRAIR Malaria Vaccine and Experimental 
Therapeutics Branches have emerged as the Department 
of Defense’s premier effort to develop vaccines and drugs 
to protect the warfighter from malaria and other infec-
tious diseases and military health threats; 
Whereas WRAIR continues to play a leadership role in the 
research and development of lifesaving medicines includ-
ing the recently approved tafenoquine, a radical cure and 
prophylaxis that protects the warfighter from P vivax re-
lapse, a condition that causes approximately 8.5 million 
clinical infections per year worldwide; 
Whereas WRAIR leads the fight against drug-resistant 
strains of malaria, developing new treatments that have 
revolutionized malaria prevention efforts; 
Whereas WRAIR’s international network of laboratories sup-
ports medical diplomacy and fosters United States-host 
nation collaborations in biomedical research; and 
Whereas WRAIR’s unique expertise, capabilities, and re-
sources have led to historic clinical trials, testing vaccines 
VerDate Sep 11 2014 
01:43 Mar 12, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR214.IH
HR214
pamtmann on DSKBFK8HB2PROD with BILLS
•HRES 214 IH 
to prevent the spread of HIV/AIDS, zika, and malaria: 
Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) supports the goals of researching new inter-
ventions to prevent and treat malaria, as it is in the 
national security, foreign affairs, political, and hu-
manitarian interest of the United States; 
(2) encourages continued leadership by the 
United States through programs such as the Walter 
Reed Army Institute of Research to ensure that the 
health of the Force is not jeopardized by vector- 
borne diseases; and 
(3) supports sustained or enhanced efforts so 
that once eliminated in a country, malaria does not 
return. 
Æ 
VerDate Sep 11 2014 
01:43 Mar 12, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR214.IH
HR214
pamtmann on DSKBFK8HB2PROD with BILLS